KEYTRUDA® (pembrolizumab) Training and Resources
KEYTRUDA® (pembrolizumab) Prescribing Information [External link]
LENVATINIB Prescribing Information [External link]
The Expert on Demand programme at MSD provides a personalised opportunity for you and your MDT to Connect with an expert in the field.
Attend interactive virtual presentations on your topic of choice followed by Q&A sessions at a time suitable for you and your team.
Explore available topic modules for the Expert on Demand programme below or submit a request for a topic that interests you
Live programme modules
Expert on Demand in non-small cell lung cancer (NSCLC)
Module 1:
Navigating with confidence: What factors determine the use of KEYTRUDA® (pembrolizumab) in PD-L1<1% mNSCLC patients?
Module 2:
Advancing early-stage NSCLC treatment: The role of KEYTRUDA® (pembrolizumab) in peri-operative and adjuvant Stage IIA to IIIB(N2) patients
Expert on Demand in Triple-Negative Breast Cancer (TNBC)
Module 1:
Advancing treatment outcomes in triple-negative breast cancer (TNBC)
Module 2:
Enhancing treatment and decision-making for triple-negative breast cancer (TNBC) patients
Expert on Demand in Melanoma
Module 1:
A surgeon’s perspective: The adjuvant Stage IIB-C melanoma patient pathway
Module 2:
Individualised care and the patient conversation
Expert on Demand in First-line Advanced Renal Cell Carcinoma (RCC)
Module 1:
Navigating the evolving landscape of first-line advanced RCC: Advocating patient care and outcomes
Module 2:
Identifying and managing IO + TKI adverse events in patients treated with pembrolizumab plus lenvatinib: A multidisciplinary approach, including case studies
Expert on Demand in Endometrial Cancer
Module 1:
Enhancing treatment options for patients with pMMR and dMMR primary advanced or recurrent endometrial cancer
Submit a request for a topic that interests you
A guide to KEYTRUDA and how to manage immune-mediated adverse events
Please refer to the SmPCs for full details about managing AEs.
Your guide to recognising and managing KEYTRUDA® (pembrolizumab) plus LENVATINIB adverse events in aRCC
Please refer to the SmPCs for full details about managing AEs.
To order printed versions of these diaries to your place of work, please contact us at msdukoncology@msd.com
Cervical cancer 
Colorectal cancer
Gastric and gastro-oesophageal
Head and neck squamous
cell carcinoma
Melanoma
Non-small cell lung cancer
Oesophageal cancer
Adjuvant Renal Cell Carcinoma
First-line advanced RCC
Triple-negative breast cancer
Urothelial carcinomaKEYTRUDA® (pembrolizumab) Prescribing Information [External link]
LENVATINIB Prescribing Information [External link]
By clicking the link above you will leave the MSD Connect website and be taken to the emc PI portal website.
KEYTRUDA as monotherapy is indicated for the treatment of adults and adolescents aged 12 years and older with advanced (unresectable or metastatic) melanoma.
Please consult the SmPC for the full list of indications and further information to minimise the risks associated with the use of the medicine before making any prescribing decisions.
